Market Cap
€786.5m
Last Updated
2019/12/12 21:00 UTC
Data Sources
Company Financials +
Executive Summary
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Imperfect balance sheet and overvalued.
Similar Companies
Share Price & News
How has Biotest's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIO3 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.0%
BIO3
5.1%
DE Biotechs
0.2%
DE Market
1 Year Return
-14.0%
BIO3
7.6%
DE Biotechs
13.6%
DE Market
Return vs Industry: BIO3 underperformed the German Biotechs industry which returned 7.6% over the past year.
Return vs Market: BIO3 underperformed the German Market which returned 13.6% over the past year.
Shareholder returns
| BIO3 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | 5.1% | 0.2% |
| 30 Day | -6.5% | 13.4% | -0.08% |
| 90 Day | -8.0% | 6.2% | 6.0% |
| 1 Year | -13.9%-14.0% | 7.8%7.6% | 17.1%13.6% |
| 3 Year | 55.0%54.0% | 78.8%76.6% | 19.6%9.0% |
| 5 Year | -35.9%-37.0% | 15.8%13.5% | 38.9%20.0% |
Price Volatility Vs. Market
How volatile is Biotest's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Biotest undervalued compared to its fair value and its price relative to the market?
1.55x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BIO3 (€20.2) is trading above our estimate of fair value (€0.43)
Significantly Below Fair Value: BIO3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIO3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BIO3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO3 is good value based on its PB Ratio (1.5x) compared to the DE Biotechs industry average (3.5x).
Next Steps
Future Growth
How is Biotest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
72.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIO3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIO3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIO3's revenue (7.8% per year) is forecast to grow faster than the German market (4.9% per year).
High Growth Revenue: BIO3's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIO3's Return on Equity is forecast to be low in 3 years time (0%).
Next Steps
Past Performance
How has Biotest performed over the past 5 years?
-19.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO3 is currently unprofitable.
Growing Profit Margin: BIO3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIO3 is unprofitable, and losses have increased over the past 5 years at a rate of -19.5% per year.
Accelerating Growth: Unable to compare BIO3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: BIO3 has a negative Return on Equity (-1.87%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Biotest's financial position?
Financial Position Analysis
Short Term Liabilities: BIO3's short term assets (€508.5M) exceed its short term liabilities (€101.1M).
Long Term Liabilities: BIO3's short term assets (€508.5M) exceed its long term liabilities (€498.2M).
Debt to Equity History and Analysis
Debt Level: BIO3's debt to equity ratio (73.3%) is considered high.
Reducing Debt: BIO3's debt to equity ratio has increased from 51.1% to 73.3% over the past 5 years.
Debt Coverage: BIO3's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BIO3's interest payments on its debt are well covered by EBIT.
Balance Sheet
Inventory Level: BIO3 has a high level of physical assets or inventory.
Debt Coverage by Assets: BIO3's debt is covered by short term assets (assets are 1.4x debt).
Next Steps
Dividend
What is Biotest's current dividend yield, its reliability and sustainability?
0.20%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: BIO3's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.34%).
High Dividend: BIO3's dividend (0.2%) is low compared to the top 25% of dividend payers in the German market (3.63%).
Stability and Growth of Payments
Stable Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BIO3 is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIO3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of Biotest's salary, the management and board of directors tenure and is there insider trading?
4.3yrs
Average management tenure
CEO
Michael Ramroth (58yo)
0.6yrs
Tenure
€1,012,000
Compensation
Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.13M) is about average for companies of similar size in the German market ($USD1.22M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.3yrs
Average Tenure
Experienced Management: BIO3's management team is considered experienced (4.3 years average tenure).
Board Age and Tenure
8.3yrs
Average Tenure
Experienced Board: BIO3's board of directors are considered experienced (8.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Michael Ramroth (58yo)
Chairman of the Management Board
- Tenure: 0.6yrs
- Compensation: €1.01m
Peter Seith
Head of Quality Operations
- Tenure: 0yrs
Georg Floß
COO & Member of the Board of Management
- Tenure: 6.9yrs
- Compensation: €888.00k
Monika Buttkereit
Head of Investor Relations
- Tenure: 0yrs
Christina Erb
Head of Corporate HR
- Tenure: 4.3yrs
Katrin Bernöster
Head of the Project Management Organisation
- Tenure: 0yrs
Jörg Schüttrumpf
Head of Research & Development
- Tenure: 0yrs
Wolfgang Möller
Head of Development - Plasma Protein
- Tenure: 0yrs
Hermann Keuper
Senior Vice President of Manufacturing
- Tenure: 0yrs
Board Members
Kerstin Birkhahn
Member of Supervisory Board
- Tenure: 9.7yrs
- Compensation: €34.00k
Rolf Hoffmann (60yo)
Chairman of the Supervisory Board
- Tenure: 0yrs
Cathrin Schleussner
Member of the Supervisory Board
- Tenure: 8.4yrs
- Compensation: €37.00k
Jurgen Heilmann
Member of Supervisory Board
- Tenure: 8.3yrs
- Compensation: €34.00k
Tan Yang
Deputy Chairman of Supervisory Board
- Tenure: 0yrs
- Compensation: €50.00k
Christine Kreidl
Supervisory Board member
- Tenure: 2.3yrs
- Compensation: €47.00k
Company Information
Biotest Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biotest Aktiengesellschaft
- Ticker: BIO3
- Exchange: XTRA
- Founded: 1946
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €786.483m
- Shares outstanding: 39.57m
- Website: https://www.biotest.com
Number of Employees
Location
- Biotest Aktiengesellschaft
- Landsteinerstrasse 5
- Dreieich
- 63303
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 0N70 | LSE (London Stock Exchange) | Yes | Preference Shares | GB | EUR | Jan 1992 |
| BIO3 | XTRA (XETRA Trading Platform) | Yes | Preference Shares | DE | EUR | Jan 1992 |
| BIO3 | DB (Deutsche Boerse AG) | Yes | Preference Shares | DE | EUR | Jan 1992 |
| BIES.F | OTCPK (Pink Sheets LLC) | Yes | Preference Shares | US | USD | Jan 1992 |
| BIO3D | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Preference Shares | GB | EUR | Jan 1992 |
| BIO3 | SWX (SIX Swiss Exchange) | Yes | Preference Shares | CH | CHF | Jan 1992 |
| BIO3 | WBAG (Wiener Boerse AG) | Yes | Preference Shares | AT | EUR | Jan 1992 |
| 0N6Z | LSE (London Stock Exchange) | Ordinary Shares | GB | EUR | Jun 1996 | |
| BIO | XTRA (XETRA Trading Platform) | Ordinary Shares | DE | EUR | Jun 1996 | |
| BIO | DB (Deutsche Boerse AG) | Ordinary Shares | DE | EUR | Jun 1996 | |
| BIOD | BATS-CHIXE (BATS 'Chi-X Europe') | Ordinary Shares | GB | EUR | Jun 1996 |
Biography
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Othe ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/12 21:00 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.